BAT8009 / Bio-Thera Solutions - LARVOL DELTA

Bio-Thera Solutions Announces Presentation of BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Selection Summit (Businesswire) - "Bio-Thera Solutions...announced that Jin-Chen Yu, SVP, Research will present a talk on BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Selection Summit taking place December 6 - 8, 2022 in Boston, MA....The talk...will present preclinical data that highlight advantages demonstrated by BAT8009 as a potential treatment for cancer patients."

Preclinical • Oncology

Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009 (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Bio-Thera Solutions | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8009, an Antibody Drug Conjugate Targeting B7-H3 (CD276) for the Treatment of Advanced Solid Tumors (Businesswire) - "Bio-Thera Solutions, Ltd...announced that dosing has begun in a Phase 1 clinical study evaluating BAT8009, an antibody drug conjugate (ADC) that targets B7-H3 (CD276). The clinical trial is a multicenter, open-label Phase 1 clinical study in patients with advanced solid tumors to evaluate the safety and tolerability of BAT8009 and to determine the recommended phase 2 dose."

Trial status • Oncology • Solid Tumor

Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009 (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Bio-Thera Solutions

New P1 trial • Oncology • Solid Tumor